Ποια είναι η τιμή για Can-Fite BioPharma Ltd. (CANF)

Η τιμή για Can-Fite BioPharma Ltd. (CANF) είναι $1.63

Ποια είναι η κεφαλαιοποίηση αγοράς για Can-Fite BioPharma Ltd. (CANF)

Η κεφαλαιοποίηση αγοράς για Can-Fite BioPharma Ltd. (CANF) είναι $70.02K

Can-Fite BioPharma Ltd. (CANF) Τιμή και Κεφαλαιοποίηση Αγοράς

Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.

Η τιμή για CANF	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$127,509,292 $70.02K	NVDA	$5.464T	+7,803,373,898.21%
$103,917,928 $70.02K	AAPL	$4.453T	+6,359,618,421.99%
$97,325,123 $70.02K	GOOG	$4.170T	+5,956,148,816.29%
$85,540,256 $70.02K	MSFT	$3.665T	+5,234,932,932.10%
$66,558,458 $70.02K	AMZN	$2.852T	+4,073,275,896.29%

Η τιμή για CANF

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$127,509,292 $70.02K